Menopause associated with increased prevalence of cardiovascular autonomic neuropathy in women with diabetes: this study

Published Date: 02 Mar 2023

Spain: A recent study showed an increase in subclinical autonomic neuropathy (CAN) in women aged 1...

Read Full News

Latest News

Diabetes Dialogue: MiniMed Vivera Data and Twiist Type 2 Clearance

Diabetes Dialogue: MiniMed Vivera Data and Twiist Type 2 Clearance

4 Endocrinology Headlines You Missed in August 2026 Chelsie Derman

New approval for tirzepatide, phase 3 wins for avexitide and retatrutide, and a GLP-1 telehealth safety gap in August's biggest endocrinology stories.

Icodec-Semaglutide Combo Outperforms Glargine in T2D Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the recent clinical success of IcoSema, an investigational insulin-semaglutide combination treatment.

Revita Reduces Weight Regain After GLP-1 Discontinuation in REMAIN-1

Revita Reduces Weight Regain After GLP-1 Discontinuation in REMAIN-1

Ultra-Rapid U500 Aspart AT278 Aids High-Dose T2D Therapy Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the recent clinical successes of ultra-fast-acting insulin AT278.

Recognizing Familial Chylomicronemia Syndrome in the APOC3 Era

Recognizing Familial Chylomicronemia Syndrome in the APOC3 Era

Todays Updates

Phase 2 ACUITY Analysis Shows Privosegtor Associated With Smaller Early NfL and GFAP Increases in Acute Optic Neuritis Isabella Ciccone, MPH

New biomarker data showed smaller post-onset increases in plasma neurofilament light chain and glial fibrillary acidic protein with privosegtor added to steroids in patients with acute optic neuritis.

CORE-VNS Study Shows Sustained Seizure Reduction With VNS Therapy at 36 Months Louie Pasculli

The 36-month CORE-VNS study findings showed sustained seizure reduction, improved quality of life, and reduced seizure-related hospitalizations among people with drug-resistant epilepsy receiving vagus nerve stimulation therapy.

The Expanding Role of Blood-Based Biomarkers in MS Care Louie Pasculli, Terrie Livingston, PharmD

Terry Livingston, PharmD, vice president of medical affairs at Octave Bioscience, discussed the evolving role of blood-based biomarkers in multiple sclerosis care.

Matching CKD Education to Patient Readiness for Home Dialysis, With Christopher Chan, MD

Matching CKD Education to Patient Readiness for Home Dialysis, With Christopher Chan, MD

Upacicalcet Lowers PTH in Secondary Hyperparathyroidism on Hemodialysis

Upacicalcet Lowers PTH in Secondary Hyperparathyroidism on Hemodialysis

Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial

Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial

Todays Updates

Phase 2 ACUITY Analysis Shows Privosegtor Associated With Smaller Early NfL and GFAP Increases in Acute Optic Neuritis Isabella Ciccone, MPH

New biomarker data showed smaller post-onset increases in plasma neurofilament light chain and glial fibrillary acidic protein with privosegtor added to steroids in patients with acute optic neuritis.

CORE-VNS Study Shows Sustained Seizure Reduction With VNS Therapy at 36 Months Louie Pasculli

The 36-month CORE-VNS study findings showed sustained seizure reduction, improved quality of life, and reduced seizure-related hospitalizations among people with drug-resistant epilepsy receiving vagus nerve stimulation therapy.

The Expanding Role of Blood-Based Biomarkers in MS Care Louie Pasculli, Terrie Livingston, PharmD

Terry Livingston, PharmD, vice president of medical affairs at Octave Bioscience, discussed the evolving role of blood-based biomarkers in multiple sclerosis care.

Matching CKD Education to Patient Readiness for Home Dialysis, With Christopher Chan, MD

Matching CKD Education to Patient Readiness for Home Dialysis, With Christopher Chan, MD

Upacicalcet Lowers PTH in Secondary Hyperparathyroidism on Hemodialysis

Upacicalcet Lowers PTH in Secondary Hyperparathyroidism on Hemodialysis

Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial

Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial

Latest News

Diabetes Dialogue: MiniMed Vivera Data and Twiist Type 2 Clearance

New approval for tirzepatide, phase 3 wins for avexitide and retatrutide, and a GLP-1 telehealth safety gap in August's biggest endocrinology stories.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the recent clinical success of IcoSema, an investigational insulin-semaglutide combination treatment.

Revita Reduces Weight Regain After GLP-1 Discontinuation in REMAIN-1

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the recent clinical successes of ultra-fast-acting insulin AT278.

Recognizing Familial Chylomicronemia Syndrome in the APOC3 Era

News All Time

REMAIN-1: Improved GLP-1-Induced Weight Loss Retention With Revita DMR System Ryan Livingston

New data from the 45-patient Midpoint Cohort, despite not being powered for statistical significance, indicate a potentially substantial benefit.

FIND-CKD Trial Poses Finerenone as a "Third Pillar" for Nondiabetic CKD Rajiv Agarwal, MD, MS

Phase 3 FIND-CKD data show finerenone slows kidney decline and reduces CV events in adults with nondiabetic CKD, Rajiv Agarwal, MD, adds his perspective.

FDA Accepts Resubmitted CAM2029 NDA for Acromegaly Ryan Livingston

FDA accepted Camurus’ resubmitted CAM2029 application for acromegaly, with a target action date of December 18, 2026.

Survey Shows Peptide Misinformation, Misuse Rising in US Ashish Rana, MD

Ashish Rana, MD, discusses Sermo’s recent clinician survey, which highlighted patients’ use of unapproved and compounded GLP-1 medications.

FDA Accepts NDA for Encaleret for Autosomal Dominant Hypocalcemia Type 1 Ryan Livingston

If approved, encaleret will be the first treatment specifically indicated for this underrepresented patient population.

Retatrutide Meets Phase 3 Weight-Loss Endpoints in 2 Obesity Trials Ryan Livingston

Retatrutide met 80-week weight-loss endpoints in TRIUMPH-2 and TRIUMPH-3, prompting a planned FDA submission in Q1 2027.

Medically Tailored Groceries Improve Blood Sugar Control, Nutrition in T2D Ryan Livingston

A recent study from Kaiser Permanente has indicated substantial HbA1c improvements among patients receiving food-based support.

5 Endocrinology Headlines You Missed in July 2026 Ryan Livingston

New Drug Applications and key trial readouts punctuated July for endocrinology, with treatments for hypocalcemia, diabetes, and more.

Continuous Glucose Monitoring in Type 2 Diabetes, With John Anderson, MD John Anderson, MD

Anderson discusses recent advancements in CGM technology, as well as the myriad behavioral and clinical benefits of CGM use in T2D with or without insulin.

TRIUMPH-2: Retatrutide Reduces Weight, A1C in Patients With Obesity Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

In this segment from the latest episode of Diabetes Dialogue, cohosts Natalie Bellini, DNP, and Diana Isaacs, PharmD, discuss the topline results of the TRIUMPH-2 trial of retatrutide.

Secret Shopper Study Reveals GLP-1 Telehealth Gaps Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the risks of ordering GLP-1 RAs online.

Ascendis Reports 78-Week Data From COACH Trial for Achondroplasia Ryan Livingston

Combination therapy with navepegritide and lonapegsomatropin has demonstrated its efficacy in improving mean annualized growth velocity in pediatric patients.

Retatrutide Cuts Weight, Cardiovascular Disease Risk in TRIUMPH-3 Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss topline data from the TRIUMPH-3 trial of retatrutide.

500,000 Patients With Diabetes May Lose Healthcare Under New Medicaid Legislation Ryan Livingston

Limits to provider taxes used to fund Medicaid programs, as well as increased eligibility requirements and cost-sharing obligations, may make insurance inaccessible.

Tirzepatide Demonstrates Cardioprotective Effects in T2D With ASCVD Ryan Livingston

In a trial comparing tirzepatide initiation with sitagliptin, the GLP-1/glucose dual agonist displayed greater reductions in major cardiovascular events.

VESALIUS-CV: Evolocumab Prevents Cardiovascular Disease in High-Risk Diabetes Marc P. Bonaca, MD, MPH

The phase 3 trial of evolocumab showed cardioprotective effects in patients without prior MI or stroke, regardless of qualifying atherosclerosis or background therapy.

Recommended News For You

No Laughing Matter: Nitrous Oxide for Transrectal Prostate Biopsy.

In inflammatory breast cancer, ER beta regulates estrogen signaling.

Some triple negative breast cancers might be avoided by longer breastfeeding

AI Model Has Promise for Predicting Checkpoint Inhibitor Activity in NSCLC

Prostate cancer, rectal exams, Casgevy approved for thalassemia, and two million cancer cases.

Study finds 1 in 12 patients labeled as having 'benign' results actually had high-risk prostate cancer

Reducing social media to an hour a day boosts young people's self-image.

Recommended Articles For You

Hematopoietic Recovery After Childhood Therapy: Mechanisms, Clinical Implications, and Emerging Strategies 

Precision Erythropoietic Modeling for Hematologic Disorders 

Comprehensive Standards in Oncology for Modern Medicine 

Modern Standards in Oncology and Patient Outcomes 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

When does a melanoma metastasize? Implications for management

2.

Asandeutertinib Tops Osimertinib for NSCLC With Brain Mets

3.

Mammography with AI support is a secure method for detecting breast cancer.

4.

Compared to previous estimates, a greater number of patients participate in cancer treatment trials.

5.

The biology of cancer as well as potential treatment options are examined by experts.

1.

Case Study: Diagnostic and Therapeutic Challenges in Aplastic Anemia Mimicking Hypoplastic Myelodysplastic Syndrome

2.

HPV and Immunotherapy in Cancer Survivorship: National Cancer Survivors Day Review

3.

Tumor-Associated Stroma Regeneration Models

4.

Colorectal Cancer Incidence Trends: A Growing Concern in 2024 and 2025

5.

Immunotherapy Tolerance in Older Adults With Cancer

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Navigating the Complexities of Ph Negative ALL - Part IX

2.

The Role of Emotional Support During Cancer Recovery

3.

Navigating the Complexities of Ph Negative ALL - Part VII

4.

Innovations in Hematology

5.

Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- A New Perspective


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot